

COVID-19 vaccine waning and effectiveness and side-effects in a
community study from the ZOE COVID Study

Lancet Infectious Diseases, The
22, 1002-1010

DOI: [10.1016/s1473-3099\(22\)00146-3](https://doi.org/10.1016/s1473-3099(22)00146-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. <i>Lancet, The</i> , 2022, 399, 1618-1624.	13.7	547
2	Implications of COVID-19 vaccine effectiveness waning for public health. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 918-919.	9.1	2
3	Benefits of integrated screening and vaccination for infection control. <i>PLoS ONE</i> , 2022, 17, e0267388.	2.5	3
5	Characterization and Outcomes of SARS-CoV-2 Infection in Overweight and Obese Patients: A Dynamic Comparison of COVID-19 Pandemic Waves. <i>Journal of Clinical Medicine</i> , 2022, 11, 2916.	2.4	12
7	Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile. <i>Vaccines</i> , 2022, 10, 924.	4.4	18
8	COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 905.	4.4	5
9	Comorbidities and covid-19. <i>BMJ, The</i> , 0, , o1431.	6.0	50
10	Liposome encapsulated clodronate mediated elimination of pathogenic macrophages and microglia: A promising pharmacological regime to defuse cytokine storm in COVID-19. <i>Medicine in Drug Discovery</i> , 2022, 15, 100136.	4.5	6
12	Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 1118-1119.	9.1	10
13	Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease. <i>Vaccines</i> , 2022, 10, 1036.	4.4	2
14	COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants. <i>Current Pharmaceutical Design</i> , 2022, 28, 2901-2913.	1.9	3
15	Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose. <i>Vaccines</i> , 2022, 10, 1115.	4.4	10
17	Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1217.	4.4	3
18	Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam. <i>Vaccines</i> , 2022, 10, 1325.	4.4	13
19	Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	9
20	Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART. <i>Vaccines</i> , 2022, 10, 1243.	4.4	17
21	Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9297.	4.1	4
22	The Adverse Reactions of Pfizer BioNTech COVID-19 Vaccine Booster Dose are Mild and Similar to the Second Dose Responses: A Retrospective Cross-Sectional Study. <i>International Journal of General Medicine</i> , 0, Volume 15, 6821-6836.	1.8	7

#	ARTICLE	IF	CITATIONS
23	Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10752.	2.6	25
24	Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection. <i>Clinical Drug Investigation</i> , 2022, 42, 799-806.	2.2	0
26	An Update on Complications Associated with SARS-CoV-2 Infection and COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1639.	4.4	1
27	Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults. <i>Clinical Infectious Diseases</i> , 2023, 76, 252-262.	5.8	7
28	Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
29	Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination. <i>Vaccines</i> , 2022, 10, 1608.	4.4	3
30	COVID-19 Infection Risk Following Elective Arthroplasty and Surgical Complications in COVID-19-vaccinated Patients: A Multicenter Comparative Cohort Study. <i>Arthroplasty Today</i> , 2022, 18, 76-83.	1.6	4
32	Vaccines and variants: an update on cardiopulmonary assessment prior to return to high-hazard occupations following COVID-19. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 177-179.	1.8	4
33	How will previous infection or current vaccination strategies protect us from future SARS-CoV-2 variant infections?. , 2022, 1, .		0
35	Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	3
36	Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
38	210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 1703.	4.4	5
39	Characteristics of hospitalized patients with SARS-CoV-2 infection during successive waves of the COVID-19 pandemic in a reference hospital in Spain. <i>Scientific Reports</i> , 2022, 12, .	3.3	10
40	Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles?. <i>Vaccines</i> , 2022, 10, 1658.	4.4	2
41	Waning immunity to SARS-CoV-2 following vaccination or infection. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	13
42	COVID-19 Vaccine Booster Dose Acceptance: Systematic Review and Meta-Analysis. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 298.	2.3	39
43	Parents' willingness to vaccinate themselves and their children with the booster vaccine against SARS-CoV-2: A cross-sectional study in Puyang city, China. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	7
44	Adverse Reactions after the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine among Medical School Residents in a Regional Reference University Hospital in Italy. <i>Vaccines</i> , 2022, 10, 1779.	4.4	1

#	ARTICLE	IF	CITATIONS
45	Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273. <i>Annals of Allergy, Asthma and Immunology</i> , 2023, 130, 67-73.	1.0	8
46	Vaccination, symptomatic infection and negative conversion of viral RNA by body mass index, diabetes, and age: An observational study. <i>Vaccine</i> , 2022, 40, 6900-6907.	3.8	1
47	Importance of Intermittent Fasting Regimens and Selection of Adequate Therapy on Inflammation and Oxidative Stress in SARS-CoV-2 Infection. <i>Nutrients</i> , 2022, 14, 4299.	4.1	3
48	Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population. <i>Vaccines</i> , 2022, 10, 1781.	4.4	17
49	COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19). <i>Cancers</i> , 2022, 14, 5547.	3.7	1
50	The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What. <i>Vaccines</i> , 2022, 10, 1924.	4.4	8
51	Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data. <i>BMC Infectious Diseases</i> , 2022, 22, .	2.9	5
52	Safety of mRNA COVID-19 Vaccines in Patients with Inborn Errors of Immunity: an Italian Multicentric Study. <i>Journal of Clinical Immunology</i> , 2023, 43, 299-307.	3.8	7
54	Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. <i>Expert Review of Vaccines</i> , 2023, 22, 1-16.	4.4	21
55	Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 1880.	4.4	16
56	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	6.9	5
57	COVID-19 Vaccination in Korea: Past, Present, and the Way Forward. <i>Journal of Korean Medical Science</i> , 2022, 37, .	2.5	20
58	Drivers of and Barriers to COVID-19 Vaccine Booster Dose Acceptance in Indonesia. <i>Vaccines</i> , 2022, 10, 1981.	4.4	3
61	Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers. <i>Vaccine</i> , 2023, 41, 365-371.	3.8	3
62	Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice. <i>Vaccines</i> , 2023, 11, 30.	4.4	3
63	Development and initial validation of the attitudes toward face mask use scale (ATFMUS). <i>Heliyon</i> , 2022, 8, e12349.	3.2	1
65	Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting. <i>Vaccine</i> , 2023, 41, 989-998.	3.8	1
66	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.9	1

#	ARTICLE	IF	CITATIONS
67	Impact of the COVID-19 Vaccination Program on case incidence, emergency department visits, and hospital admissions among children aged 5â€“17 Years during the Delta and Omicron Periodsâ€“United States, December 2020 to April 2022. PLoS ONE, 2022, 17, e0276409.	2.5	2
68	Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses. Emerging Microbes and Infections, 2023, 12, .	6.5	2
70	Considerations in Understanding Vaccine Effectiveness. Vaccines, 2023, 11, 20.	4.4	0
71	Differences in BNT126b2 and ChAdOx1 Homologous Vaccination Antibody Response among Teachers in Poznan, Poland. Vaccines, 2023, 11, 118.	4.4	0
72	COVID-19 vaccine and booster hesitation around the world: A literature review. Frontiers in Medicine, 0, 9, .	2.6	17
73	Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme. Vaccines, 2023, 11, 182.	4.4	2
74	A Recent Update on SARS-CoV-2 Transmission and its Variants: Transmission, Pathogenic Mechanism, and Treatment. Coronaviruses, 2023, 4, .	0.3	1
75	Preference and Willingness to Pay for the Regular COVID-19 Booster Shot in the Vietnamese Population: Theory-Driven Discrete Choice Experiment. JMIR Public Health and Surveillance, 0, 9, e43055.	2.6	7
76	Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	5
77	Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies. ELife, 0, 12, .	6.0	8
78	Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance. Tropical Medicine and Infectious Disease, 2023, 8, 91.	2.3	4
79	Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. Trends in Molecular Medicine, 2023, 29, 255-267.	6.7	17
81	Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study. Vaccines, 2023, 11, 247.	4.4	7
82	Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2. Frontiers in Immunology, 0, 14, .	4.8	5
83	Evaluating the Adverse Events Associated with Three Doses of the COVID-19 Vaccination in Adults in the Western Region of Saudi Arabia: A Cross-Sectional Study. Vaccines, 2023, 11, 266.	4.4	1
84	Hesitancy to Receive the Booster Doses of COVID-19 Vaccine Among Cancer Patients in China: A Multicenter Cross-Sectional Survey â€“ Four PLADs, China, 2022. China CDC Weekly, 2023, 5, 223-228.	2.3	8
85	COVID-19 Vaccine Booster Dose Acceptance among Older Adults. Vaccines, 2023, 11, 542.	4.4	3
86	Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern. Npj Vaccines, 2023, 8, .	6.0	7

#	ARTICLE	IF	CITATIONS
87	Incidence and Associated Factors of SARS-CoV-2 Infection Post-mRNA-1273 Booster Vaccination in Health-Care Workers. <i>Vaccines</i> , 2023, 11, 481.	4.4	2
88	Incremental Net Benefit and Incremental Cost-Effectiveness Ratio of COVID-19 Vaccination Campaigns: Systematic Review of Cost-Effectiveness Evidence. <i>Vaccines</i> , 2023, 11, 347.	4.4	1
89	SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection. <i>Nature Communications</i> , 2023, 14, .	12.8	25
90	Hesitancy to Receive the Second COVID-19 Vaccine Booster Dose among Older Adults in Hong Kong: A Random Telephone Survey. <i>Vaccines</i> , 2023, 11, 392.	4.4	6
91	Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. <i>Lancet Respiratory Medicine</i> , 2023, 11, 439-452.	10.7	69
92	Development and validation mental training model: Mental Toughness Training Circle (MTTC). <i>F1000Research</i> , 0, 12, 169.	1.6	0
93	Impact of COVID-19 vaccination on COVID-19 hospital admissions in England during 2021: an observational study. <i>Journal of the Royal Society of Medicine</i> , 0, , 014107682311570.	2.0	1
94	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	1.6	0
95	Differences in attitude toward COVID-19 based on internet and social media usage among community-dwelling older adults during the first state of emergency. <i>Geriatrics and Gerontology International</i> , 2023, 23, 289-296.	1.5	1
96	Racial/Ethnic Differences in Risk Factors Associated With Severe COVID-19 Among Older Adults With ADRD. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 855-861.e7.	2.5	1
97	Identification of Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2. <i>Microorganisms</i> , 2023, 11, 717.	3.6	1
99	Antibody response to the COVID-19 ChAdOx1nCoV-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2). <i>RMD Open</i> , 2023, 9, e002871.	3.8	4
100	Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. <i>Nature Communications</i> , 2023, 14, .	12.8	12
101	mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
102	Determination of significant immunological timescales from mRNA-LNP-based vaccines in humans. <i>Journal of Mathematical Biology</i> , 2023, 86, .	1.9	2
103	Pathophysiological effects of SARS-CoV-2 infection on the cardiovascular system and its clinical manifestations—a mini review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	3
104	Evaluating the reactogenicity of COVID-19 vaccines from network-meta analyses. <i>Expert Review of Vaccines</i> , 2023, 22, 410-418.	4.4	2
105	Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity. <i>JAMA Network Open</i> , 2023, 6, e2310650.	5.9	60

#	ARTICLE	IF	CITATIONS
106	Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
107	The effectiveness of COVID-19 vaccination against all-cause mortality in patients with type 2 diabetes mellitus: The observation during the initial period of the cancellation of the Dynamic Zero Policy in mainland China. <i>Diabetes Research and Clinical Practice</i> , 2023, 200, 110694.	2.8	2
108	Awareness and Hesitancy of COVID-19 and other Vaccines among People Living with HIV/AIDS Attending Antiretroviral Therapy (ART) Center in North India. <i>Indian Journal of Community Medicine</i> , 2023, 48, 492-496.	0.4	1
109	Are We Facing a Tsunami of Vaccine Hesitancy or Outdated Pandemic Policy in Times of Omicron? Analyzing Changes of COVID-19 Vaccination Trends in Poland. <i>Vaccines</i> , 2023, 11, 1065.	4.4	3
110	Long-term Real-world Protection Afforded by Third mRNA Doses Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections, Coronavirus Disease 19-related Emergency Attendances and Hospitalizations Amongst Older Singaporeans During an Omicron XBB Wave. <i>Clinical Infectious Diseases</i> , 2023, 77, 1111-1119.	5.8	6
111	Confronting COVID: Crisis Leadership, Turbulence and Governance: Does the Coronavirus Pandemic Exhibit Deliberate Deception or Gross Incompetence?. , 2023, , 557-580.		0
112	Predictors of older adults' attitudes toward various COVID-19 vaccine mandates. <i>Journal of Aging and Social Policy</i> , 0, , 1-14.	1.6	0
113	Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens. <i>Vaccine</i> , 2023, 41, 4879-4887.	3.8	5
114	Attitudes toward annual COVID-19 boosters are highly structured by partisan self-identification and trust in government: Evidence from a longitudinal survey. <i>Vaccine: X</i> , 2023, 14, 100337.	2.1	0
115	High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses. <i>Journal of Clinical Virology Plus</i> , 2023, 3, 100156.	1.0	4
117	Exploring the intention and hesitancy to receive a booster dose of COVID-19 vaccine among patients with comorbid disease conditions using a health belief model. <i>Vacunas</i> , 2023, 24, 317-325.	2.0	3
118	Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice. <i>Npj Vaccines</i> , 2023, 8, .	6.0	2
120	COVID-19, post-acute COVID-19 syndrome (PACS, long COVID) and post-COVID-19 vaccination syndrome (PCVS, post-COVIDvac-syndrome): Similarities and differences. <i>Pathology Research and Practice</i> , 2023, 246, 154497.	2.3	16
121	PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals. <i>Scientific Reports</i> , 2023, 13, .	3.3	10
122	Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. <i>Nature Communications</i> , 2023, 14, .	12.8	38
123	Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands. <i>Vaccine</i> , 2023, 41, 4319-4326.	3.8	3
124	The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	3
125	Optimal control and stability analysis of an age-structured SEIRV model with imperfect vaccination. <i>Mathematical Biosciences and Engineering</i> , 2023, 20, 14438-14463.	1.9	1

#	ARTICLE	IF	CITATIONS
126	SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis. <i>Vaccines</i> , 2023, 11, 1184.	4.4	4
127	Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis. <i>Lancet Regional Health - Europe</i> , The, 2023, 31, 100675.	5.6	1
128	Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial. <i>Journal of Infection</i> , 2023, 87, 242-254.	3.3	5
129	SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. <i>Nature Medicine</i> , 2023, 29, 1760-1774.	30.7	27
131	Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR) Tj ETQq0 0 0 rgBT /Overlock 1 <i>Vaccines</i> , 2023, 11, 1234.	4.4	1
132	The influence of COVID-19 risk perception and vaccination status on the number of social contacts across Europe: insights from the CoMix study. <i>BMC Public Health</i> , 2023, 23, .	2.9	5
133	Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses. <i>BMJ</i> , The, 0, , e074325.	6.0	4
134	Identification of an optimized Receptor-Binding Domain Subunit Vaccine against SARS-CoV-2. <i>Journal of Immunology</i> , 0, , .	0.8	0
135	Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study. <i>EClinicalMedicine</i> , 2023, 62, 102109.	7.1	7
136	Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly. <i>Cell Reports</i> , 2023, 42, 112991.	6.4	6
137	Clinical symptom profile of hospitalized COVID-19 Brazilian patients according to SARS-CoV-2 variants. <i>Epidemiology and Health</i> , 0, 45, e2023079.	1.9	3
138	Protection against Severe Illness versus Immunityâ€”Redefining Vaccine Effectiveness in the Aftermath of COVID-19. <i>Microorganisms</i> , 2023, 11, 1963.	3.6	3
139	Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial. <i>BMJ</i> , The, 0, , e070464.	6.0	2
140	Risks of Adverse Outcomes for Hospitalized COVID-19 Patients during the Four Waves in Brazil According to SARS-CoV-2 Variants, Age Group, and Vaccine Status. <i>Viruses</i> , 2023, 15, 1997.	3.3	1
141	Nationwide analysis of the impact of COVID-19 in patients with a cardiovascular, oncological or chronic pulmonary disease in the context of an Eastern European country with a low vaccination rate, Bulgaria: March 2020â€”April 2022. <i>BMJ Open</i> , 2023, 13, e068431.	1.9	1
142	Mucosal antibody responses following Vaxzevria vaccination. <i>Immunology and Cell Biology</i> , 2023, 101, 975-983.	2.3	0
143	Profile and Outcomes of Hospitalized COVID-19 Patients during the Prevalence of the Omicron Variant According to the Brazilian Regions: A Retrospective Cohort Study from 2022. <i>Vaccines</i> , 2023, 11, 1568.	4.4	0
144	Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVIDâ€™19 vaccine Ad26.COVS.2 in humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 1485-1498.	2.5	0

#	ARTICLE	IF	CITATIONS
145	COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19). <i>Cancers</i> , 2023, 15, 4777.	3.7	0
146	Association between Lipid Levels, Anti-SARS-CoV-2 Spike Antibodies and COVID-19 Mortality: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 5068.	2.4	0
148	Real-world effectiveness of COVID-19 vaccines among Colombian adults: A retrospective, population-based study of the ESPERANZA cohort. <i>PLOS Global Public Health</i> , 2023, 3, e0001845.	1.6	0
151	Association between BNT162b2 vaccination and health-related quality of life up to 18 months post-SARS-CoV-2 infection in Israel. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
152	Multivariate Analysis of Adverse Reactions and Recipient Profiles in COVID-19 Booster Vaccinations: A Prospective Cohort Study. <i>Vaccines</i> , 2023, 11, 1513.	4.4	0
153	Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development. <i>International Journal of Molecular Sciences</i> , 2023, 24, 14622.	4.1	0
154	SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study. <i>Journal of Infection</i> , 2023, 87, 506-515.	3.3	3
155	Immunogenicity of ChAdOx1 (Covishield) Booster Dose in Healthcare Providers: A Pre-Post Study. <i>Cureus</i> , 2023, , .	0.5	0
156	IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers. <i>Medicine (United States)</i> , 2023, 102, e35444.	1.0	0
157	Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals. <i>PLoS Pathogens</i> , 2023, 19, e1011744.	4.7	2
158	A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports. <i>European Journal of Medical Research</i> , 2023, 28, .	2.2	0
159	Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial. <i>Lancet Rheumatology</i> , The, 2024, 6, e21-e30.	3.9	2
160	Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial. <i>The Lancet Regional Health - Western Pacific</i> , 2024, 42, 100953.	2.9	1
161	Exploring the intention and hesitancy to receive a booster dose of COVID-19 vaccine among patients with comorbid disease conditions using a health belief model. <i>Vacunas (English Edition)</i> , 2023, 24, 317-325.	0.2	0
162	The intention to get COVID-19 booster vaccination and its association with cognitive and emotional factors: A survey of Chinese COVID-19 infected people in Hong Kong. <i>Vaccine</i> , 2024, 42, 206-212.	3.8	0
163	Anti-SARS-CoV-2 Antibody Testing: Role and Indications. <i>Journal of Clinical Medicine</i> , 2023, 12, 7575.	2.4	1
164	ANÁLISE DO PERFIL VACINAL CONTRA O COVID-19 DA CIDADE DE CARUARU-PE. , 2023, 3, 24698-24715.		0
165	Cross-sectional surveillance study of long COVID in Toyonaka city, Osaka prefecture, Japan. <i>Journal of Infection and Chemotherapy</i> , 2023, , .	1.7	0

#	ARTICLE	IF	CITATIONS
166	Temporal changes to adult case fatality risk of COVID-19 after vaccination in England between May 2020 and February 2022: a national surveillance study. <i>Journal of the Royal Society of Medicine</i> , 0, , .	2.0	1
167	Long-term immune response to Omicron-specific mRNA vaccination in mice, hamsters, and nonhuman primates. <i>MedComm</i> , 2023, 4, .	7.2	1
168	The spectrum of side effects associated with COVID-19 vaccines in patients with inborn errors of immunity. <i>Clinical Immunology</i> , 2023, , 109878.	3.2	0
169	Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
170	Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021-2022. <i>Swiss Medical Weekly</i> , 2023, 153, 3502.	1.6	0
171	A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects. <i>Antiviral Research</i> , 2024, 222, 105789.	4.1	0
172	Changes in Local and Systemic Adverse Effects following Primary and Booster Immunisation against COVID-19 in an Observational Cohort of Dutch Healthcare Workers Vaccinated with BNT162b2 (Comirnaty®). <i>Vaccines</i> , 2024, 12, 39.	4.4	0
173	An analysis of the waning effect of COVID-19 vaccinations. <i>Genomics and Informatics</i> , 2023, 21, e50.	0.8	0
174	Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines. <i>Vaccines</i> , 2024, 12, 57.	4.4	0
175	Effect of the number of coronavirus disease 2019 (COVID-19) vaccination shots on the occurrence of pneumonia, severe pneumonia, and death in SARS-CoV-2-infected patients. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	0
176	Remdesivir for the Treatment of COVID-19: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2024, 13, 1-19.	4.0	0
177	No Waning of Pneumococcal Vaccine Responses over Time in People with Inflammatory Arthritis: Findings from a Single Centre Cohort. <i>Vaccines</i> , 2024, 12, 69.	4.4	0
178	The descriptive epidemiology of pre-omicron SARS-CoV-2 breakthrough infections and severe outcomes in Manitoba, Canada. , 0, 3, .		0
179	High-titer manufacturing of SARS-CoV-2 Spike-pseudotyped VSV in stirred-tank bioreactors. <i>Molecular Therapy - Methods and Clinical Development</i> , 2024, 32, 101189.	4.1	0
180	Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants. <i>Journal of Immunology Research</i> , 2024, 2024, 1-19.	2.2	0
182	Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants. <i>Current Microbiology</i> , 2024, 81, .	2.2	0
183	Prognostic value of anti-SARS-CoV-2 antibodies: a systematic review. <i>Clinical Chemistry and Laboratory Medicine</i> , 2024, 62, 1029-1043.	2.3	1
184	Diabetes and COVID-19 Outcomes: An Analysis of Freeman Health System Patients. <i>Cureus</i> , 2024, , .	0.5	0

#	ARTICLE	IF	CITATIONS
185	Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection. <i>Nature Communications</i> , 2024, 15, .	12.8	0
186	AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: The RAVEN cohort study. <i>Journal of Infection</i> , 2024, 88, 106129.	3.3	0
187	Willingness to receive the second booster of COVID-19 vaccine among older adults with cancer: a stratified analysis in four provinces of China. <i>Frontiers in Public Health</i> , 0, 12, .	2.7	0
188	The effect of public health interventions on COVID-19 incidence in Queensland, Australia: a spatial cluster analysis. <i>Infectious Diseases</i> , 2024, 56, 460-475.	2.8	0
189	Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. <i>Nature Communications</i> , 2024, 15, .	12.8	0
190	Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study. <i>Vaccine</i> , 2024, 42, 2357-2369.	3.8	0
191	Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador. <i>Clinical and Experimental Vaccine Research</i> , 2024, 13, 35.	2.2	0
192	Assessing the dynamics and impact of COVID-19 vaccination on disease spread: A data-driven approach. <i>Infectious Disease Modelling</i> , 2024, 9, 527-556.	1.9	0